The present meta-analysis suggests that serum OPG levels can reflect prostate cancer bone metastasis to some extent, which indicates that serum OPG measurements can be used to supplement existing diagnostic methods for bone metastasis. This evidence concerns the gene TNFRSF11B and prostate cancer.